Abstract
The author reviewed recent findings on pharmacotherapy of social anxiety disorder (SAD). Meta-analyses and RCTs have suggested that SSRIs, SNRIs and RIMAs are significantly effective on social anxiety disorder compared with placebo. In Japan, however, RIMA is not available and venlafaxine (an SNRI effective on SAD) is not approved for the treatment of SAD using public health insurance. SSRIs may therefore currently play the most important role in pharmacotherapy of SAD in Japan.
